Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-6 and IL-6 Receptor Proteins

IL-6 and IL-6 Receptor Proteins

IL-6 and IL-6 Receptor Proteins

In 1973, Interleukin 6 (IL-6) was identified as a soluble factor secreted by T cells, which is essential for the production of antibodies by B cells. Since its discovery nearly 50 years ago, the IL-6 signaling pathway has emerged as a key pathway involved in immune regulation in health and immune dysregulation in many diseases.

In the classical pathway, IL-6 binds to both transmembrane and soluble forms of its receptor IL-6 R,namely mIL-6R and sIL-6R. After that, the complex binds to the Glycoprotein 130(gp130) and downstream signaling and gene expression are triggered. In the trans- signaling pathway, the complex of sIL-6 with the receptor binds to gp130, and intracellular signal transduction is initiated. In the next step, the JAK-STAT, RAS-RAF, and other pathways are activated, promoting cellular proliferation, differentiation, oxidative stress, and immune regulation. The classical IL-6 signal is limited to the cells (macrophages, neutrophils, T cells, etc.) that express IL-6R. But when IL-6 levels are elevated, the signal is widely expressed due to the ubiquitous nature of gp130.

IL-6 signaling pathway

Furthermore, emerging evidence suggests that dysregulation of IL-6 contributes to a variety of disease states, including various types of cancer development, progression, and metastasis, increased levels of IL-6 are associated with a higher risk of cancer and other diseases, such as insulin resistance, asthma, coronary heart disease, advanced cancer, and can also serve as a prognostic marker for cancer. Targeting this pathway may expand to the treatment of several other symptoms, such as uveitis, neuromyelitis optica, and more recently, COVID-19 pneumonia.

ACROBiosystems has developed a series of high-quality IL-6 and IL-6 receptor proteins to facilitate the development of IL-6 related drugs.

Product Features

Human and Mouse species are available

High purity:>95%

High bioactivity verified by ELISA, BLI and cell-based assay. Free protocols offered

Various tags:Tag Free,His Tag,Avi & His Tag,Fc Tag

Low endotoxin:< 1.0 EU/μg

Product List
Molecule Cat. No. Species Product Description Preorder/Order
Verification Data

High purity is more than 95% as verified by SDS-PAGE

Biotinylated Human IL-6 R alpha, Avitag, His Tag (Cat. No. CD6-H82E8) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%. The protein has a calculated MW of 41.7 kDa and migrates as 55-70 kDa due to glycosylation.

High bioactivity verified by ELISA

Immobilized ActiveMax® Human IL-6, Tag Free (Cat. No. IL6-H4218) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha, Avitag, His Tag (Cat. No. CD6-H82E8) with a linear range of 4-125 ng/mL.

High bioactivity verified by BLI

Loaded Human IL-6 R alpha, Fc Tag (Cat. No. ILR-H5259) on Protein A Biosensor, can bind ActiveMax® Human IL-6, Tag Free (Cat. No. IL6-H4218) with an affinity constant of 35.9 nM as determined in BLI assay (ForteBio Octet Red96e).

High bioactivity verified by cell-based assay

ActiveMax® Human IL-6, Tag Free (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2856-0.3636 ng/mL.

Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL.

Related Reading

>>【Inspiring Target】Therapeutic potential of IL-6 immunization in multiple fields continues to burst


1. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16, 335–345 (2020).

2. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?. Pharm Med 34, 223–231 (2020).

3. Computer-aided prediction and design of IL-6 inducing peptides: IL-6 plays a crucial role in COVID-19. Briefings in Bioinformatics. 2021, 22(2): 936–945.

4. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021,326(6):499–518.

  • Authors: The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.

  • Download Full Article

5. Why tocilizumab could be an effective treatment for severe COVID-19?. J Transl Med 18, 164 (2020).

ACRO Quality

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message